The Soluble α Chain of Interleukin-15 Receptor: A Proinflammatory Molecule Associated with Tumor Progression in Head and Neck Cancer

Abstract

Interleukin (IL)-15 is a proinflammatory cytokine, as it induces the production of inflammatory cytokines [IL-6, tumor necrosis factor A (TNFA), etc.]. A correlation between high intratumoral IL-15 concentrations and poor clinical outcome in lung and head and neck cancer patients has been recently reported. The purpose of this study was to investigate the role of the soluble A chain of IL-15 receptor (sIL-15RA), a natural regulator of IL-15, in head and neck cancer. Fifty-three newly diagnosed untreated head and neck cancer patients were included in this study. Quantification of sIL-15RA was performed with a newly developed RIA. Increased serum sIL-15RA concentrations were found in head and neck cancer patients and were closely correlated with poor clinical outcome both in terms of locoregional control and survival even on multivariate analysis. sIL-15RA was mainly produced by tumor cells via proteolytic cleavage of IL-15RA mediated by ADAM-17. A correlation was observed between ADAM-17 expression in tumor cells and serum sIL-15RA concentrations. Surprisingly, sIL-15RA did not act in vitro as an IL-15 antagonist but rather as an enhancer of IL-15-induced proinflammatory cytokines TNFA, that may promote tumor progression. This new tumor evasion mechanism based on amplification of the intratumoral inflammatory reaction is probably not restricted to head and neck cancer, as other tumors have been shown to release sIL-15RA. Overall, these results support for the first time an original protumor role of sIL-15RA in cancer.

Immune infiltration in human tumors: a prognostic factor that should not be ignored

“…Furthermore, under the pressure of antitumoral immune activity, selection and outgrowth of variant tumor cells with reduced immunogenicity could occur (Smyth et al, 2001;Dunn et al, 2004Dunn et al, , 2006. Thus, during cancer progression tumor cells may acquire immune tolerance mechanisms by generating complex immunosuppressive networks at the tumor site (Zou, 2005;Kim et al, 2006), involving IL-10, transforming growth factor-b (TGF-b) or soluble IL-15 receptors (Badoual et al, 2008), and T-cell-specific co-inhibitory molecules (CTLA-4 and PD-1) (Egen et al, 2002;Okazaki and Honjo, 2006).…”

Tumor-Infiltrating Regulatory T Cells: Phenotype, Role, Mechanism of Expansion In Situ and Clinical Significance

“…Third, specific subsets of Tregs, in particular those expressing activation markers such as CCR4, may exert more robust immunosuppressive functions, and hence be more closely associated with prognosis, than the entire population of Tregs [107]. Fourth, some oncogenic programs, such as those underlying (at least some instances of) lymphoma [108], head and neck cancer [109,110], gastric cancer [111] and colorectal carcinoma [112], involve a prominent pro-inflammatory component. In this setting, Treg-mediated immunosuppression may exert bona fide antitumor functions.…”

An Antibody Fusion Protein for Cancer Immunotherapy Mimicking IL-15 trans-Presentation at the Tumor Site

“…case, soluble IL-15Ra might arise from proteolytic cleavage of the membrane form by metalloproteinases (14,15).…”